Type 2 Diabetes

Top Tips for a Happy Holiday: Keys to Diabetes Management

From eating to drinking to being merry, the holiday season poses a unique set of challenges for people with diabetes. Endocrinology Advisor has compiled a ...

Bariatric Surgery: An Effective Treatment for Type 2 Diabetes

Bariatric surgery appears to induce changes in the gastrointestinal tract and its interactions with the endocrine system in ways that may influence glycemic control.

Addressing Psychological Insulin Resistance in Patients With Diabetes

Learn about strategies to reduce a patient's reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.

Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging

Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.

In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D

Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes.

Poorly Controlled Rheumatoid Arthritis Increases T2D Risk

Type 2 diabetes is significantly underdiagnosed and undertreated in patients with rheumatoid arthritis.

Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?

Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD ...

Video

Latest Headlines

HbA1c Predicts Risk for T2D in African American, White Patients

HbA1c Predicts Risk for T2D in African American, White Patients

Investigators believe that type 2 diabetes risk assessment would be optimal with fasting glucose and HbA1c levels.

Remotely Connected Diabetes System Improves Glycemic Control in Insulin-Treated Diabetes

Remotely Connected Diabetes System Improves Glycemic Control in Insulin-Treated Diabetes

A remotely connected diabetes management system increased patent satisfaction and improved glycemic control in patients with insulin-treated diabetes.

Insulin Associated With BMD Loss at Femoral Neck in Women With T2D

Insulin Associated With BMD Loss at Femoral Neck in Women With T2D

Bone mineral density was evaluated annually of the lumbar spine and femoral neck.

DPP4 Inhibitors Provide Greater Long-Term Glycemic Control Than Sulfonylureas

DPP4 Inhibitors Provide Greater Long-Term Glycemic Control Than Sulfonylureas

Investigators discuss an added benefit of using DPP4 inhibitors would be a lower incidence of hypoglycemia.

FDA: Semaglutide Approval for Adults With T2D

FDA: Semaglutide Approval for Adults With T2D

Semaglutide, a once-weekly GLP-1 receptor agonist, demonstrated clinically significant reductions in HbA1c among adults with type 2 diabetes.

Voluntary Recall of Diabetes Drug Due to Possible Microbial Contamination

Voluntary Recall of Diabetes Drug Due to Possible Microbial Contamination

The Food and Drug Administration has posted a recall notification for 2 lots of Riomet 500mg/5mL due to the possibility that the liquid may be contaminated with Scopulariopsis brevicaulis.

Insulin-Induced Weight Gain Not Associated With Adverse CV Outcomes in T2D

Insulin-Induced Weight Gain Not Associated With Adverse CV Outcomes in T2D

Despite the well‐recognized correlation between weight gain and cardiovascular (CV) disease, there is little direct evidence relating to the impact of insulin‐induced weight gain on CV outcomes.

Incident Diabetes May Explain Association Between Sleep Duration and CHD

Incident Diabetes May Explain Association Between Sleep Duration and CHD

Interventions targeting sleep duration could have a significant impact on health outcomes when considering the importance of diabetes for a wide range of diseases.

Renal Outcomes in T2D With Intensive Glycemic Control in Veterans

Renal Outcomes in T2D With Intensive Glycemic Control in Veterans

Interim analysis of the follow-up Veterans Affairs Diabetes Trial study shows that intensive glycemic control for a median of 5.6 years may have a modest beneficial effect on delaying the progression of renal disease.

No Difference in Cardiovascular Outcomes With Exenatide vs Placebo in T2D

No Difference in Cardiovascular Outcomes With Exenatide vs Placebo in T2D

Once-weekly administration of extended-release exenatide in patients with T2D at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.

Sign Up for Free e-Newsletters

CME Focus